Skip to content
CompoundSci
All peptides
Research vial labelled Wolverine (BPC-157 + TB-500), a Healing and tissue peptide studied in preclinical and clinical literature

Wolverine (BPC-157 + TB-500)

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

A pre-mixed repair blend. Because the two half-lives are wildly different, one component is always mistimed.

General profile

Class
Healing and tissue
Evidence
Early or preclinical only
Studied dose range
Per component, commonly 250 mcg + 2 mg
Frequency in protocols
Daily to twice weekly depending on the blend
Route
Subcutaneous
Half life
Mixed, hours to days
Reconstitution
3 mL bacteriostatic water per blended vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the morning window

Daily

The BPC-157 component wants daily dosing while the TB-500 component lasts days. Running the blend daily overdoses one side of it over time.

Reported cycle: 6 weeks on, 4 weeks off

Follows the TB-500 loading arc since that is the slower component of the blend.

Watch for: The same angiogenesis caution as both components separately, plus the fact that you cannot dose them independently.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopBody level hard stop

    Wolverine (BPC-157 + TB-500) + The window right after cardiac surgery

    Not alongside an active cardiac recovery regimen

    Bleeding risk and the cardiac drug regimen come first. Pro-angiogenic and vasodilatory compounds can clash with that care. Physician territory, not a timing problem.

  • Hard stopBody level hard stop

    Wolverine (BPC-157 + TB-500) + Active cancer, pregnancy or heavy immunosuppression

    Absolute stop with an active cancer history

    Angiogenesis is the whole mechanism people are chasing here, and it acts everywhere in the body, not only in the tendon you care about. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference.

  • Hard stopTiming

    Wolverine (BPC-157 + TB-500) + BPC-157

    Duplicate ingredient

    The Wolverine blend already contains BPC-157. Adding it separately double doses one half of the blend while leaving the other half unchanged.

  • Hard stopTiming

    Wolverine (BPC-157 + TB-500) + TB-500

    Duplicate ingredient

    TB-500 is already in the blend and has a multi-day half-life, so an additional standalone dose accumulates fast.

  • Pick oneRedundant, pick one

    Wolverine (BPC-157 + TB-500) + TB-500

    Same target hit twice

    Wolverine is BPC-157 plus TB-500. Running both doubles one half of the pair.

  • Pick oneRedundant, pick one

    Wolverine (BPC-157 + TB-500) + BPC-157

    Same target hit twice

    Wolverine already contains BPC-157.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Wolverine (BPC-157 + TB-500) fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Search the full literature